Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05496296 · ClinicalTrials.gov registry record · NA
Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
A NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II, sponsored by ULURU.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 14
- Study locations
NCT05496296: Recruiting NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II, sponsored by ULURU.
NCT05496296 is a NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II that is actively recruiting participants, run by ULURU. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05496296, a NA study of Pressure Ulcer, Stage IV and Pressure Ulcers Stage II, is actively recruiting participants, sponsored by ULURU.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 14
- Study locations
Study Summary
Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care treatment (as recommended by the National Pressure Injury Advisory Panel) to treatment with Altrazeal® in patients with stage 2, stage 3 and stage 4 pressure injury wounds. Altrazeal® is a Class 1, 501(k) exempt medical device listed with the FDA as a "dressing, wound, hydrogel" and has an extended wear time of up to 30 days. Subjects can be enrolled in the study either as an outpatient, or while hospitalized. Half of the subjects will be randomized to standard of care treatment, and the other half will be randomized to Altrazeal®. There are a total of up to 12 study visits taking place over 12 weeks.
Primary Outcome
The number of primary dressing changes for each treatment group will be compared.
Conditions Studied
Interventions
- DEVICE Altrazeal® Transforming Powder Dressing
Study Locations (14)
New York
- Northwell Health System/Zucker School of Medicine - Lake Success
- NYU Langone Hospital-Long Island - Mineola
- James J. Peters VA Medical Center - The Bronx
- Westchester Medical Center, 100 Woods, Road, Taylor Care Pavillion - Valhalla
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
- MedStar National Rehabilitation Hospital - Washington D.C.
Maryland
- Medstar Franklin Square Medical Center - Baltimore
- Medstar Good Samaritan Hospital - Baltimore
Texas
- VA North Texas Healthcare System - Dallas
- Michael E. DeBakey Houston VAMC - Houston
California
- San Diego VA - San Diego
Illinois
- Northwestern Medicine - Chicago
New Jersey
- Rutgers New Jersey Medical School, Ambulatory Care Center-Wound Care Clinic - Newark
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Presbyterian - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-04-30 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT05496296 shows while recruiting
NCT05496296 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Pressure Ulcer, Stage IV appearing as the primary indexed condition, and to 1 intervention - of which Altrazeal® Transforming Powder Dressing is the first listed.
NCT05496296 lists 14 locations in 8 states (New York, District of Columbia, Maryland).
Frequently Asked Questions
What is clinical trial NCT05496296 about?
NCT05496296 is a clinical study titled "Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries". Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care ...
What is the current status of trial NCT05496296?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-04-30. Estimated completion is 2026-12.
What conditions does trial NCT05496296 study?
This clinical trial studies the following conditions: Pressure Ulcer, Stage IV, Pressure Ulcers Stage II, Pressure Ulcers Stage III.
What interventions are being tested in trial NCT05496296?
The interventions under investigation include: Altrazeal® Transforming Powder Dressing (DEVICE).
Who is sponsoring clinical trial NCT05496296?
This trial is sponsored by ULURU, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05496296 being conducted?
This trial has 14 study locations across California, District of Columbia, Illinois, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pressure Ulcer, Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05496296's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI